Enrica Antonia Martino, Ernesto Vigna, Antonella Bruzzese, Caterina Labanca, Francesco Mendicino, Eugenio Lucia, Virginia Olivito, Annamaria Zimbo, Federica Torricelli, Antonino Neri, Fortunato Morabito, Massimo Gentile
INTRODUCTION: Selinexor, an XPO1 inhibitor, has emerged as a promising therapeutic option in the challenging landscape of relapsed/refractory multiple myeloma (RRMM). AREAS COVERED: This article provides a review of selinexor, with a focus on available clinical studies involving MM patients and its safety profile. Clinical trials, such as STORM and BOSTON, have demonstrated its efficacy, particularly in combination regimens, showcasing notable overall response rates (ORR) and prolonged median progression-free survival (mPFS)...
March 19, 2024: Expert Opinion on Pharmacotherapy